LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
VIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia Commercial product launch initiated in October 2025 with broad product availability in mid-Q4 2025 Over 2,500 ECPs prescribed VIZZ, 40% of which have prescribed multiple times, resulting in over 5,000 prescriptions filled through October 2025 Partnered with Sarah Jessica Parker as direct-to-consumer campaign spokesperson; anticipated to launch in Q1 2026 Pro forma cash, cash equivalents and marketable secur ...